EMA explains cuts to Humira clinical trial documents
This article was originally published in SRA
Executive Summary
The European Medicines Agency has written to the European ombudsman giving its reasons for redacting certain information from three clinical study reports on AbbVie's Humira (adalimumab before releasing them in response to a citizen's access to documents request1-3.